|Bid||68.04 x 1000|
|Ask||68.89 x 1100|
|Day's range||67.08 - 68.59|
|52-week range||60.57 - 94.87|
|Beta (5Y monthly)||1.02|
|PE ratio (TTM)||29.21|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair (TEER) therapies, as well as one-year results from the CLASP IID registry. The studies confirm the clinical and quality-of-life benefits of mitral regurgitation (MR) reduction with the PASCAL system in a broad population of patients with degenerative mitral regurgitation (DMR). Results from th
Edwards Lifesciences Corporation (NYSE: EW) today announced successful results from TRISCEND II, a randomized controlled pivotal trial designed to evaluate the safety and effectiveness of the groundbreaking EVOQUE tricuspid valve replacement system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization.
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2023.